Skip to: Content
Skip to: Site Navigation
Skip to: Search

September 5, 2008 10:49:35 PM CDT

Learn about Newser Points »

« Back to the grid | Next story »

Bone Drug Reduces Breast Cancer Relapse

Posted May 31, 08 7:21 PM CDT in Science & Health 

(Newser) – A drug designed to protect cancer patients' bones also renders breast cancer relapses less likely, a new study says. Funded in part by the drug's maker, Novartis, researchers found that even two injections of Zometa a year cut tumor recurrence by 35% in more than 1,800 pre-menopausal women.

About 6% of women who took Zometa suffered a tumor relapse, compared to 9% who didn't. A doctor unaffiliated with the study warned women not to gobble up the drug, but said that “within the narrowly defined group of women who got the drug, this study would give one strong impetus to use Zometa.''

Source Bloomberg

0 comments | Print E-mail | Digg Seed this on Newsvine Add this link to Del.icio.us StumbleUpon
A production plant of Swiss pharma giant Novartis.   (AP Photo/Keystone, Gaetan Bally)
The headquarters of Swiss pharmaceutical company Novartis.   (AP Photo/Keystone, Steffen Schmidt)
Misdiagnosis of breast cancer and other health problems are growing (Photo   (AP Photo)
« Prev« Prev | Next »Next » Slideshow
Our editors also recommend:

Threads (1 of 2)

Tags

breast cancer  • scientific study  • osteoporosis  • Novartis AG  • bone cancer  • off label drug use


Loading...

Premium Articles from HighBeam

Find more articles like this

Today's Most Popular


Other Science & Health Stories

What is Newser?

2008 Codie Finalist

Newser gives you more news in less time. We search for the best and most important stories all over the web, read them for you, and deliver concise and sharp summaries—along with links to the full text. Newser provides a way to stay on top of an ever-expanding horizon of news and opinion—politics, sports, business, trends, technology, personalities, crimes, and controversies. Newser keeps you not just better informed, but, with our signature graphic interface and smart condensed format, more enjoyably informed.

Learn more »